Predictor of Liver Biochemistry Improvement in Patients with Cytomegalovirus Cholestasis after Ganciclovir Treatment
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Cholestasis resulting from cytomegalovirus (CMV)-induced hepatitis manifests in 40% of patients with a CMV infection. Ganciclovir treatment in children with CMV infections has proven to be highly effective. Until now, there are very few studies have identified predictive factors for liver biochemistry improvement after ganciclovir therapy. This study aimed to identify the predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Methods: A retrospective cohort study was conducted using medical records from Dr. Sardjito General Hospital Yogyakarta, Indonesia from 2013 to 2018. CMV cholestasis was confirmed based on serum CMV IgG and IgM positivity and/or blood and urine CMV antigenemia positivity. Incomplete medical records and other etiologies for cholestasis, such as biliary atresia, choledochal cyst, metabolic diseases, and Alagille syndrome, were excluded. Patient age at cholestasis diagnosis and ganciclovir treatment, duration of CMV cholestasis, history of prematurity, central nervous system involvement, and nutritional status were analyzed and presented as an odds ratio (OR) with a 95% confidence interval (95% CI). Results: CMV cholestasis with ganciclovir therapy was found in 41 of 54 patients. Multivariate analysis showed that a shorter duration of CMV cholestasis (OR: 4.6, 95% CI: 1.00-21.07, p=0.04) was statistically significant for liver biochemistry improvement after 1 month of ganciclovir treatment. The remaining factors that were analyzed were not significant predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Conclusion: A shorter duration of CMV cholestasis is the predictor of liver biochemistry improvement after 1 month gancyclovir treatment.
Abstract
Purpose: Cholestasis resulting from cytomegalovirus (CMV)-induced hepatitis manifests in 40% of patients with a CMV infection. Ganciclovir treatment in children with CMV infections has proven to be highly effective. Until now, there are very few studies have identified predictive factors for liver biochemistry improvement after ganciclovir therapy. This study aimed to identify the predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Methods: A retrospective cohort study was conducted using medical records from Dr. Sardjito General Hospital Yogyakarta, Indonesia from 2013 to 2018. CMV cholestasis was confirmed based on serum CMV IgG and IgM positivity and/or blood and urine CMV antigenemia positivity. Incomplete medical records and other etiologies for cholestasis, such as biliary atresia, choledochal cyst, metabolic diseases, and Alagille syndrome, were excluded. Patient age at cholestasis diagnosis and ganciclovir treatment, duration of CMV cholestasis, history of prematurity, central nervous system involvement, and nutritional status were analyzed and presented as an odds ratio (OR) with a 95% confidence interval (95% CI). Results: CMV cholestasis with ganciclovir therapy was found in 41 of 54 patients. Multivariate analysis showed that a shorter duration of CMV cholestasis (OR: 4.6, 95% CI: 1.00-21.07, p=0.04) was statistically significant for liver biochemistry improvement after 1 month of ganciclovir treatment. The remaining factors that were analyzed were not significant predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Conclusion: A shorter duration of CMV cholestasis is the predictor of liver biochemistry improvement after 1 month gancyclovir treatment.
참고문헌 (17)
- Brooks GF, "Jawetz, Melnick, & Adelberg’s medical microbiology", pp.480~483 (2013), McGraw-Hill
- Hasosah MY, "Perinatal cytomegalovirus hepatitis in Saudi infants : a case series", Saudi J Gastroenterol, 18, pp.208~213 (2012)
- Liberek A, "Cytomegalovirus disease in neonates and infants--clinical presentation, diagnostic and therapeutic problems--own experience", Med Sci Monit, 8, pp.815~820 (2002)
- Tezer H, "Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children", Turk J Pediatr, 50, pp.228~234 (2008)
- Dollard SC, "New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection", Rev Med Virol, 17, pp.355~363 (2007)
- Leonardsson H, "Hepatitis due to Epstein-Barr virus and cytomegalovirus : clinical features and outcomes", Scand J Gastroenterol, 52, pp.893~897 (2017)
- Whitley RJ, "Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group", J Infect Dis, 175, pp.1080~1086 (1997)
- Mattar RH, "Nutritional status and intestinal iron absorption in children with chronic hepatic disease with and without cholestasis", J Pediatr(Rio J), 81, pp.317~324 (2005)
- Rosenthal P, "Liver disease in children", pp.232~246 (2007), Cambridge University Press
- 민채연, "Characteristics and prognosis of hepatic cytomegalovirus infection in children: 10 years of experience at a university hospital in Korea", Clinical and Experimental Pediatrics, 60(8), pp.261~265 (2017), 대한소아청소년과학회
- Tezer H, "Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity", Turk J Med Sci, 46, pp.1629~1633 (2016)
- Schleiss MR, "Congenital cytomegalovirus infection : molecular mechanisms mediating viral pathogenesis", Infect Disord Drug Targets, 11, pp.449~465 (2011)
- Ross SA, "Congenital cytomegalovirus infection : outcome and diagnosis", Semin Pediatr Infect Dis, 16, pp.44~49 (2005)
- Pawłowska J, "The role of cytomegalovirus infection in pathogenesis of neonatal cholestasis", Exp Clin Hepatol, 6, pp.25~29 (2010)
- Kunno A, "Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults", Liver, 17, pp.129~132 (1997)
- Greanya ED, "The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients : a review of the British Columbia experience", Can J Infect Dis Med Microbiol, 16, pp.335~341 (2005)
- Ross SA, "Overview of the diagnosis of cytomegalovirus infection", Infect Disord Drug Targets, 11, pp.466~474 (2011)